Qualitative interviews with 43 patients on capivasertib plus fulvestrant found the 4-on/3-off dosing schedule broadly acceptable, while identifying gaps in hyperglycemia recognition and willingness to use supportive medications.
Michael F. Barry
Advertisement
Articles by Michael F. Barry
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Understanding The Training, Credentialing Landscapes for End-of-Life Doulas
2
Epcoritamab Combo Shows Sustained Remissions in Follicular Lymphoma
3
Olomorasib Earns FDA Breakthrough Therapy in KRAS G12C+ Pancreatic Cancer
4
GLP-1 Receptor Agonists and Cancer: Renewed Momentum for Metabo-Oncology
5